BIOCAD is developing a new drug for melanoma treatment

At this time BIOCAD is studying several molecules. The most successful candidate will become a new product in 2018-2019.

Candidate molecules are monoclonal antibodies to PD-1 antigen that stimulate patient immune system to destroy cancer cell. BIOCAD is planning to launch 1-2 new generation drugs every year starting in…

Read more

245 companies worldwide are developing 700 biosimilars

The market is biologics may exceed 250 bln USD by 2020. Biosimilars, copies of biologics, are becoming more popular. According to Reuters 245 companies worldwide are currently developing 700 biosimilars.

Biggest players are Teva, Sandoz, Pfizer, and Amgen. Biosimilars popularity can be explained by their profitability:…

Read more

Biologics with a total of $67 bln in global sales will lose patent protection by 2020

Twelve biologics with total global sales of $67 bln will meet generics competition by 2020.

Read more

Common drug registration rules for countries in the Customs Union are anticipated by 2016

Currently drugs are the only commodity that cannot move freely between Russia, Belarus and Kazakhstan.

Read more

Pfizer is interested in acquiring Actavis in order to avoid high US taxes

Similar proposition by Pfizer was rejected for the fourth time by AstraZeneca earlier this year.

Read more

Analysts are anticipating market growth in 2014

RNC Pharma is forecasting the retail sector to grow by 10-12%, hospital sector – 12-15%.

Read more

USA budget will save 250 bln USD by 2014 by switching to biosimilars

Biosimilars have been available in Europe since 2006. Novartis is currently waiting on FDA decision on its first in the US biosimilar of Neupogen.

Read more

Russian companies developed and submitted to the Minister of Health Veronika Skvortsova a proposal of rules governing studies of biosimilars

A number of Russian companies including BIOCAD, Generium, GEROPHARM, ChemRar, R-pharm, Sotex, Pharmstandard and others developed Rules for conducting studies of biosimilars.

Read more